Targeting dendritic cells to drive PDAC immunotherapy response.
1/5 보강
Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells.
APA
Weinstein AG, DeNardo DG (2024). Targeting dendritic cells to drive PDAC immunotherapy response.. Trends in pharmacological sciences, 45(12), 1095-1096. https://doi.org/10.1016/j.tips.2024.10.009
MLA
Weinstein AG, et al.. "Targeting dendritic cells to drive PDAC immunotherapy response.." Trends in pharmacological sciences, vol. 45, no. 12, 2024, pp. 1095-1096.
PMID
39510862
Abstract
Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.
MeSH Terms
Dendritic Cells; Humans; Immunotherapy; Pancreatic Neoplasms; Animals; Cancer Vaccines; Carcinoma, Pancreatic Ductal